ArticleNeoplasia (New York, N.Y.)
Exceptionally potent anti-tumor bystander activity of an scFv:sTRAIL fusion protein with specificity for EGP2 toward target antigen-negative tumor cells.
Article in Neoplasia (New York, N.Y.). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 52 citations in OpenAlex.
- Engineering of CD19 Antibodies: A CD19-TRAIL Fusion Construct Specifically Induces Apoptosis in B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) Cells In Vivo.Journal of clinical medicine · 2021Article
- Molecular Mode of Action of TRAIL Receptor Agonists-Common Principles and Their Translational Exploitation.Cancers · 2019Review
- Antibodies and Derivatives Targeting DR4 and DR5 for Cancer Therapy.Antibodies (Basel, Switzerland) · 2017Review
- CSPG4: A Target for Selective Delivery of Human Cytolytic Fusion Proteins and TRAIL.Biomedicines · 2017Review
- Targeted induction of apoptosis in glioblastoma multiforme cells by an MRP3-specific TRAIL fusion protein in vitro.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Article
- Targeted delivery of tumor necrosis factor-related apoptosis-inducing ligand to keratinocytes with a pemphigus mAb.The Journal of investigative dermatology · 2013Article
- Targeting of the tumor necrosis factor receptor superfamily for cancer immunotherapy.ISRN oncology · 2013Article
- Tumor cell-selective apoptosis induction through targeting of K(V)10.1 via bifunctional TRAIL antibody.Molecular cancer · 2011Article
- Melanoma-associated Chondroitin Sulfate Proteoglycan (MCSP)-targeted delivery of soluble TRAIL potently inhibits melanoma outgrowth in vitro and in vivo.Molecular cancer · 2010Article
- A novel molecule integrating therapeutic and diagnostic activities reveals multiple aspects of stem cell-based therapy.Stem cells (Dayton, Ohio) · 2010Article
- Article
- Humanized immunotoxins: a new generation of immunotoxins for targeted cancer therapy.Cancer science · 2009Review
- Death receptors as targets for anti-cancer therapy.Journal of cellular and molecular medicine · 2008Review
- Targeted delivery of a designed sTRAIL mutant results in superior apoptotic activity towards EGFR-positive tumor cells.Journal of molecular medicine (Berlin, Germany) · 2008Article
- EpCAM homologues exhibit epithelial-specific but different expression patterns in the kidney.Transgenic research · 2008Article
- Selective induction of apoptosis in leukemic B-lymphoid cells by a CD19-specific TRAIL fusion protein.Cancer immunology, immunotherapy : CII · 2008Article
- RGD-avidin-biotin pretargeting to alpha v beta 3 integrin enhances the proapoptotic activity of TNF alpha related apoptosis inducing ligand (TRAIL).Apoptosis : an international journal on programmed cell death · 2008Article
- The promise of TRAIL--potential and risks of a novel anticancer therapy.Journal of molecular medicine (Berlin, Germany) · 2007Review
- A review of the past, present, and future directions of neoplasia.Neoplasia (New York, N.Y.) · 2005Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Previously, we reported on the target cell-restricted fratricide apoptotic activity of scFvC54:sTRAIL, a fusion protein comprising human-soluble tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) genetically linked to the antibody fragment scFvC54 specific for the cell surface target antigen EGP2. In the present study, we report that the selective binding of scFvC54:sTRAIL to EGP2-positive target cells conveys an exceptionally potent pro-apoptotic effect toward neighboring tumor cells that are devoid of EGP2 expression (bystander cells). The anti-tumor bystander activity of scFvC54:sTRAIL was detectable at target-to-bystander cell ratios as low as 1:100. Treatment in the presence of EGP2-blocking or TRAIL-neutralizing antibody strongly inhibited apoptosis in both target and bystander tumor cells. In the absence of target cells, bystander cell apoptosis induction was abrogated. The bystander apoptosis activity of scFvC54:sTRAIL did not require internalization, enzymatic conversion, diffusion, or communication (gap junctional intracellular communication) between target and bystander cells. Furthermore, scFvC54:sTRAIL showed no detectable signs of innocent bystander activity toward freshly isolated blood cells. Further development of this new principle is warranted for approaches where cancer cells can escape from antibody-based therapy due to partial loss of target antigen expression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.